Volume 42, Issue 6, Pages (June 2005)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Host – hepatitis C viral interactions: The role of genetics
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Volume 125, Issue 1, Pages (July 2003)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Volume 42, Issue 1, Pages (January 2005)
Volume 125, Issue 1, Pages (July 2003)
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 66, Issue 4, Pages (April 2017)
Hepatitis C-associated B-cell non-Hodgkin lymphomas
Immigration and viral hepatitis
Volume 42, Issue 1, Pages (January 2005)
Volume 66, Issue 1, Pages 1-4 (January 2017)
The evidence supports a viral aetiology for primary biliary cirrhosis
Living donor liver transplantation: is the hype over?
The origin of cancer stem cells
Volume 42, Issue 1, Pages (January 2005)
De Novo Ceramide Synthesis Participates in the Ultraviolet B Irradiation-Induced Apoptosis in Undifferentiated Cultured Human Keratinocytes  Yoshikazu.
ChREBP in NASH – A liver transcription factor comes in from the cold
Volume 44, Issue 4, Pages (April 2006)
Volume 42, Issue 2, Pages (February 2005)
Volume 66, Issue 1, Pages (January 2017)
Hepatitis C core protein – The “core” of immune deception?
Burcin Ekser, Eric Lagasse  Journal of Hepatology 
Targeting gut flora to prevent progression of hepatocellular carcinoma
Volume 18, Issue 3, Pages (June 2011)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Hepatic hepcidin expression is decreased in cirrhosis and HCC
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
JNK mediates hepatic ischemia reperfusion injury
George T. Kannarkat, Dean J. Tuma, Pamela L. Tuma 
EASL Clinical Practice Guidelines: Wilson’s disease
Folic acid protects against lead acetate-induced hepatotoxicity by decreasing NF-κB, IL- 1β production and lipid peroxidation mediataed cell injury  Eman.
Volume 42, Issue 3, Pages (March 2005)
Volume 62, Issue 6, Pages (June 2015)
Volume 65, Issue 2, Pages (August 2016)
Volume 59, Issue 2, Pages (August 2013)
Volume 41, Issue 6, Pages (December 2004)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Volume 42, Issue 6, Pages (June 2005)
Fen Huang, Chenchen Yang, Xinying Zhou, Wenhai Yu, Qiuwei Pan 
Liver stem cells—prospects for clinical use
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 44, Issue 6, Pages (June 2006)
Volume 61, Issue 1, Pages S79-S90 (November 2014)
Volume 44, Issue 2, Pages (February 2006)
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Volume 64, Issue 6, Pages (June 2016)
Immunological techniques in viral hepatitis
Volume 63, Issue 1, Pages (July 2015)
Macrophage heterogeneity in liver injury and fibrosis
Volume 41, Issue 6, Pages (December 2004)
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Volume 44, Issue 3, Pages (March 2006)
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Genetics of hepatocellular carcinoma: The next generation
Host – hepatitis C viral interactions: The role of genetics
Niya Aleksieva, Stuart J. Forbes  Journal of Hepatology 
Volume 44, Issue 6, Pages (June 2006)
Volume 64, Issue 6, Pages (June 2016)
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Presentation transcript:

Volume 42, Issue 6, Pages 870-879 (June 2005) Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats  Marc G. Jeschke, Hauke Rensing, Dagmar Klein, Thomas Schubert, Anke EM Mautes, Ulrich Bolder, Roland S Croner  Journal of Hepatology  Volume 42, Issue 6, Pages 870-879 (June 2005) DOI: 10.1016/j.jhep.2004.12.036 Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Serum glucose decreased in both groups LPS and LPS+insulin compared to normal levels. There were no significant differences between LPS vs. LPS+insulin. Data presented as means±SEM with n=7 each group and each time point. Journal of Hepatology 2005 42, 870-879DOI: (10.1016/j.jhep.2004.12.036) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 2 A–D: (A) Serum albumin decreased immediately after LPS administration and remained low throughout the study. Insulin increased serum albumin at days 1, 2, 5 and 7 post LPS when compared to LPS. *Significant difference between LPS+insulin vs. LPS, P<0.05. Data presented as means±SEM with n=7 each group and each time point. (B) Serum CRP increased after LPS injection and remained elevated. Insulin administration significantly decreased serum CRP levels at all days when compared to controls. *Significant difference between LPS+insulin vs. LPS, P<0.05. Data presented as means±SEM with n=7 each group and each time point. (C) Endotoxemia caused a significant increase in serum AST immediately after LPS administration. Insulin significantly decreased serum AST at days 1 and 2 compared to LPS. *Significant difference between LPS+insulin vs. LPS, P<0.05. Data presented as means±SEM with n=7 each group and each time point. (D) Insulin decreased serum ALT at the first two days after LPS injection. *Significant difference between LPS+insulin vs. LPS, P<0.05. Data presented as means±SEM with n=7 each group and each time point. Journal of Hepatology 2005 42, 870-879DOI: (10.1016/j.jhep.2004.12.036) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 3 ATP was found to be present in normal animals. Endotoxemia caused decreased levels of intracellular hepatic ATP. There were no significant differences between LPS and LPS+insulin. Intrahepatic glucose levels are low. LPS caused an increase of intrahepatic glucose levels, which were decreased to normal concentration with insulin administration. Rats receiving LPS+insulin had normal hepatic glucose levels, P<0.05. Endotoxemia caused a significant increase in lactate, whereas animals receiving LPS+insulin had normal lactate levels, P<0.05. Absorbance was measured and values are shown in Table 1. n=3 for normal and n=4 for LPS and LPS+insulin in each group. Color interpretation from highest to lowest concentration: red>orange>yellow>green>light blue>dark blue. Journal of Hepatology 2005 42, 870-879DOI: (10.1016/j.jhep.2004.12.036) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Hepatic genes in endotoxemic and endotoxemic plus insulin treated animals 24h after endotoxemia with n=3 for each group. Out of 15,000 genes, 88 genes were significantly up-regulated (red color), and 51 were significantly down-regulated (green color). Details are given in Table 2. Journal of Hepatology 2005 42, 870-879DOI: (10.1016/j.jhep.2004.12.036) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 5 A--C: (A) Endotoxemia caused a significant increase in hepatocyte apoptosis compared to normal. Insulin administration decreased hepatocyte apoptosis at all time points. *Significant difference between insulin and control, P<0.05. Data presented as means±SEM with n=7 for each group and each time point. (B) Insulin significantly increased hepatocyte proliferation on days 1, 5 and 7 compared to controls. *Significant difference between insulin and control, P<0.05. Data presented as means±SEM with n=7 for each group and each time point. (C) In order to determine net cell balance proliferation was divided by apoptosis. Insulin significantly improved cellular net balance by stimulating cell survival compared to controls on all study days. *Significant difference between insulin and control, P<0.05. Data presented as means±SEM with n=7 for each group and each time point. Journal of Hepatology 2005 42, 870-879DOI: (10.1016/j.jhep.2004.12.036) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 6 A–B: (A) Hepatic caspase-3 increased compared to normal. Insulin prevented the increase on the first and second day after LPS compared to controls. *Significant difference between insulin and control, P<0.05. Data presented as means±SEM with n=7 for each group and each time point. (B) Bcl-2 was decreased during endotoxemia. Insulin significantly increased Bcl-2 protein levels in the liver 2 and 5 days after LPS. *Significant difference between insulin and control, P<0.05. Data presented as means±SEM with n=7 for each group and each time point. Journal of Hepatology 2005 42, 870-879DOI: (10.1016/j.jhep.2004.12.036) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions